Phase III MAIA study of Darzalex + Revlimid + dexamethasone shows survival benefits in multiple myeloma – Janssen Biotech
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.
